Key facts
- This page summarizes Roger Garceau's Form 4 filing for Entera Bio Ltd. (ENTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2024, 16:21.
Roger Garceau - 01 Jan 2024 Form 4 Insider Report for Entera Bio Ltd. (ENTX)
- Reporting relationship
- Director
- Issuer ticker
- ENTX
- Reported as of
- 01 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 16:21:24 UTC
- Prior SEC filing
- 08 Jun 2023
- Next SEC filing
- 10 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dana Yaacov-Garbeli, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roger Garceau filed Form 4 for Entera Bio Ltd. (ENTX) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +108,333
- Change %
- Price
- $0.000000
- Shares after
- 108,333
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares, par value NIS 0.0000769 per share
- Underlying amount
- 108,333
- Exercise price
- $0.6000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.